On August 12, 2026, Sellas Life Sciences is trading at $11.93, +8.15% following its August 11 second-quarter report, which matched the $0.05 loss-per-share estimate.
- Investor focus remains on the pivotal Phase 3 REGAL trial approaching its 80-event final-analysis trigger, alongside approximately $138.3 million in cash.
- The earnings release also highlighted advancing regulatory preparations and increased clinical spending.